JES
Senior Member
- Messages
- 1,372
A couple of years ago there was news about Fluoxetine (Prozac) being discovered as an enterovirus antiviral, though its effect was only analyzed in vitro [1][2]. Today I stumbled upon a new article on the application of Fluoxetine for HCV, which caught my interest, as this study was performed on humans [3].
I have CFS symptoms resembling of enteroviral infection, including myocarditis which is typically caused by Coxsackie B3 virus. So I decided to start a trial on Fluoxetine in the next couple of weeks, as I couldn't find any reports on it online for this particular application. I will be reporting on my progress here, hopefully shortly.
I have CFS symptoms resembling of enteroviral infection, including myocarditis which is typically caused by Coxsackie B3 virus. So I decided to start a trial on Fluoxetine in the next couple of weeks, as I couldn't find any reports on it online for this particular application. I will be reporting on my progress here, hopefully shortly.
Antiviral Res. 2014 Oct;110:158-67. doi: 10.1016/j.antiviral.2014.08.002. Epub 2014 Aug 21.
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.
Young KC1, Bai CH2, Su HC3, Tsai PJ1, Pu CY2, Liao CS4, Lin YM4, Lai HW4, Chong LW4, Tsai YS5, Tsao CW6.
Author information
Abstract
More than 20% of chronic hepatitis C (CHC) patients receiving interferon-alpha (IFN-α)-based anti-hepatitis C virus (HCV) therapy experienced significant depression, which was relieved by treatment with fluoxetine. However, whether and how fluoxetine affected directly the anti-HCV therapy remained unclear. Here, we demonstrated that fluoxetine inhibited HCV infection and blocked the production of reactive oxygen species (ROS) and lipid accumulation in Huh7.5 cells. Fluoxetine facilitated the IFN-α-mediated antiviral actions via activations of signal transducer and activator of transcription (STAT)-1 and c-Jun amino-terminal kinases (JNK). Alternatively, fluoxetine elevated peroxisome proliferator-activated receptor (PPAR) response element activity under HCV infection. The inhibitory effects of fluoxetine on HCV infection and lipid accumulation, but not production of ROS, were partially reversed by the PPAR-β, -γ, and JNK antagonists. Furthermore, fluoxetine intervention to the IFN-α-2b regimen facilitated to reduce HCV titer and alanine transaminase level for CHC patients. Therefore, fluoxetine intervention to the IFN-α-2b regimen improved the efficacy of anti-HCV treatment, which might be related to blockades of ROS generation and lipid accumulation and activation of host antiviral JNK/STAT-1 and PPARβ/γ signals.
Copyright © 2014 Elsevier B.V. All rights reserved.
KEYWORDS:
Fluoxetine; Hepatitis C virus; Interferon-α; JNK; PPAR-β/γ; STAT-1